During Monday’s Current trade, Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), gain 0.74% to $70.84.
Teva Pharmaceutical Industries Ltd. (TEVA) and privately-held Immuneering Corporation recently declared that the companies have reached a contract in which Teva will purchase a 51% equity share of the genomic-analysis company. Immuneering uses advanced proprietary techniques to identify hidden signals and biological insights across an array of genetic, genomic, and proteomic data that can direct research for improved discovery, development and clinical success.
Teva and Immuneering have worked together over the past several years to unlock noteworthyfindings into genetic biomarkers, therapy-specific gene expression signatures and breakthrough work in characterizing non-biological complex drugs (NBCDs). Teva’s majority holding in Immuneering provides right of first refusal in projects regardingthe Company’s stated objective of developing, personalizing and improving treatment of disorders of the Central Nervous System (CNS).
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic or branded generic medicines; specialized products, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances; and active pharmaceutical ingredients. The Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, in addition to the womens health, oncology, and other specialty businesses.
Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), inclined 1.88% to $252.05, during its current trading session.
Biotech company Pharming Group N.V. published its (unaudited) financial report for the six months ended 30 June 2015.
FINANCIAL HIGHLIGHTS
- Revenues from operations raised to €5.2 million (H1 2014: €2.5 million) as a result of substantially raised revenues from product sales of €4.1 million (€2.9 million for Q2), contrast to €1.4 million for H1 2014. Revenues from Ruconest® sales in the US amounted to €3.0 million (€2.4 million for Q2) and in the EU amounted to €1.1 million (€0.5 million for Q2).
- Gross profit raised to €2.9 million (€2.1 million for Q2) from €0.7 million in H1 2014 as a result of sales in the US and a gain on inventory impairments, reflecting the improving yields from sales in the US and direct commercialisation in the EU.
- As result of increasing costs of operations (R&D, General and Administrative and Marketing and Sales), operating result reduced by €0.7 million, to a loss of €6.1 million contrast to a €5.4 million loss for H1 2014. The enhance is mostly a result of the (non-cash) share-based compensation.
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, in addition to Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer.
Rayonier Inc. (NYSE:RYN), during its Monday’s current trading session gained 1.13% to $23.30.
Rayonier Inc. (RYN) declared that the company’s board of directors has declared a third quarter cash dividend of $0.25 per common share. The dividend is payable on September 30, 2015 to shareholders of record on September 16, 2015.
Rayonier Inc. operates as an investment arm of Rayonier TRS Operating Company. Rayonier, Inc. engages in the sale and development of real estate and timberland administration, in addition to in the production and sale of cellulose fibers in the United States, New Zealand, and Australia. The company operates in four segments: Timber, Real Estate, Performance Fibers, and Wood Products.
Finally, Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), gained 4.26%, to $1.13.
Sunesis Pharmaceuticals, Inc. (SNSS) declared that Daniel Swisher, Chief Executive Officer of Sunesis, will present at the 2015 Wedbush PacGrow Healthcare Conference on Wednesday, August 12th at 10:20 AM Eastern Time at Le Parker Meridien Hotel in New York City.
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has accomplished a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
